References
- RigelDSEpidemiology of melanomaSemin Cutan Med Surg201029420420921277533
- SiegelRNaishadhamDJemalACancer statistics, 2013CA Cancer J Clin2013631113023335087
- FrankSJMeyerMInterferon as adjuvant therapy for high-risk melanomaMelanoma Lett19951314
- National Comprehensive Cancer NetworkNCCN Clinical Practice Guidelines in Oncology: MelanomaNational Comprehensive Cancer Network, Version 42011 Available from: http://www.nccn.org/professionals/physician_gls/pdf/melanoma.pdfAccessed October 30, 2014
- KirkwoodJMStrawdermanMHErnstoffMSSmithTJBordenECBlumRHInterferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684J Clin Oncol19961417178558223
- KirkwoodJMIbrahimJGSondakVKHigh- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190J Clin Oncol200018122444245810856105
- AgarwalaSSLeeSJFlahertyLERandomized phase III trial of high-dose interferon alfa-2b (HDI) for 4 weeks induction only in patients with intermediate- and high-risk melanoma (Intergroup trial E 1697)J Clin Oncol201129527s
- MocellinSLensMBPasqualiSPilatiPChiarion SileniVInterferon alpha for the adjuvant treatment of cutaneous melanomaCochrane Database Syst Rev20136CD00895523775773
- PuntCJEggermontAMAdjuvant interferon-α for melanoma revisited: news from old and new studiesAnn Oncol200112121663166611843241
- DummerRHauschildAGuggenheimMKeilholzUPentheroudakisGESMO Guidelines Working GroupCutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201223Suppl 7vii86vii9122997461
- HillnerBEKirkwoodJMAtkinsMBJohnsonERSmithTJEconomic analysis of adjuvant interferon alfa-2b in high-risk melanoma based on projections from Eastern Cooperative Oncology Group 1684J Clin Oncol1997156235123589196150
- CormierJNXingYDingMCost effectiveness of adjuvant interferon in node-positive melanomaJ Clin Oncol200725172442244817557957
- Intron® [product information]Kenilworth, NJSchering-Plough Corporation2009
- KilbridgeKLColeBFKirkwoodJMQuality-of-life-adjusted survival analysis of high-dose adjuvant interferon alpha-2b for high-risk melanoma patients using intergroup clinical trial dataJ Clin Oncol20022051311131811870174
- HackshawMDKrishnaAMauroDJRetrospective US database analysis of drug utilization patterns, health care resource use, and costs associated with adjuvant interferon alfa-2b therapy for treatment of malignant melanoma following surgeryClinicoecon Outcomes Res2012416917622754281
- LymanGHThe evolution of clinical trials in oncology: randomised controlled trials to real world studiesAnn Oncol201425Supplement 4iv41iv42
- US Bureau of Labor Statistics [homepage on the Internet]Consumer price index2001 Available from: http://www.bls.gov/cpi/Accessed February, 2012
- DeyoRACherkinDCCiolMAAdapting a clinical comorbidity index for use with ICD-9-CM administrative databasesJ Clin Epidemiol19924566136191607900
- DavisKLMitraDKotapatiSIbrahimRWolchokJDDirect economic burden of high-risk and metastatic melanoma in the elderly: evidence from the SEER-Medicare linked databaseAppl Health Econ Health Policy200971314119558193
- KotapatiSDavisKLMitraDIloejeUTreatment patterns in high risk and metastatic melanoma: Evidence from linked electronic medical records and administrative claims dataJ Clin Oncol200826Suppl Abstr 17540
- KeffordRFAdjuvant therapy of cutaneous melanoma: the interferon debateAnn Oncol200314335836512598338
- PayneMJArgyropoulouKLoriganPPhase II pilot study of intravenous high-dose interferon with or without maintenance treatment in melanoma at high risk of recurrenceJ Clin Oncol201432318519024344211
- KirkwoodJMBenderCAgarwalaSMechanisms and management of toxicities associated with high-dose interferon alfa-2b therapyJ Clin Oncol200220173703371812202672
- LehmannAAslaniPAhmedRAssessing medication adherence: options to considerInt J Clin Pharm2014361556924166659